Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Maire F Osborn"'
Autor:
Mehran Nikan, Maire F Osborn, Andrew H Coles, Bruno MDC Godinho, Lauren M Hall, Reka A Haraszti, Matthew R Hassler, Dimas Echeverria, Neil Aronin, Anastasia Khvorova
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 5, Iss C (2016)
The use of siRNA-based therapies for the treatment of neurodegenerative disease requires efficient, nontoxic distribution to the affected brain parenchyma, notably the striatum and cortex. Here, we describe the synthesis and activity of a fully chemi
Externí odkaz:
https://doaj.org/article/403e7fbdd7a741a5a8aaa26b35ee95f1
Autor:
Julia F Alterman, Lauren M Hall, Andrew H Coles, Matthew R Hassler, Marie-Cecile Didiot, Kathryn Chase, Jasmin Abraham, Emily Sottosanti, Emily Johnson, Ellen Sapp, Maire F Osborn, Marian Difiglia, Neil Aronin, Anastasia Khvorova
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 4, Iss C (2015)
Applications of RNA interference for neuroscience research have been limited by a lack of simple and efficient methods to deliver oligonucleotides to primary neurons in culture and to the brain. Here, we show that primary neurons rapidly internalize
Externí odkaz:
https://doaj.org/article/8deb88f2d18041e482886315f7d242aa
Autor:
Anastasia Khvorova, Miguel Sena-Esteves, Jonathan K. Watts, Michael P. Moazami, Dimas Echeverria, Diane Golebiowski, Andrew H. Coles, Maire F. Osborn
Glioblastoma (GBM) is the most common and lethal form of primary brain tumor with dismal median and 2-year survivals of 14.5 months and 18%, respectively. The paucity of new therapeutic agents stems from the complex biology of a highly adaptable tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01d609951d687c95196190cb7b9e136c
https://doi.org/10.1158/1535-7163.c.6538093.v1
https://doi.org/10.1158/1535-7163.c.6538093.v1
Autor:
Anastasia Khvorova, Miguel Sena-Esteves, Jonathan K. Watts, Michael P. Moazami, Dimas Echeverria, Diane Golebiowski, Andrew H. Coles, Maire F. Osborn
Figure S1. Cytotoxicity of Chol-hsiRNAs in vitro Table S1. Tumor-associated luciferase activity Table S2. Chol-hsiRNA sequences and chemical modification patterns
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f9b0bae80aadbb09e57195d5697103d
https://doi.org/10.1158/1535-7163.22505506.v1
https://doi.org/10.1158/1535-7163.22505506.v1
Autor:
Andrew H. Coles, Annabelle Biscans, Maire F. Osborn, Bruno M.D.C. Godinho, Loic Roux, Anastasia Khvorova, Mehran Nikan, Socheata Ly, Matthew R. Hassler, Dimas Echeverria, Reka A. Haraszti, Sarah M. Davis
Publikováno v:
Nucleic Acids Research
Efficient delivery of therapeutic RNA beyond the liver is the fundamental obstacle preventing its clinical utility. Lipid conjugation increases plasma half-life and enhances tissue accumulation and cellular uptake of small interfering RNAs (siRNAs).
Autor:
Diane Golebiowski, Miguel Sena-Esteves, Maire F. Osborn, Michael P. Moazami, Dimas Echeverria, Jonathan K. Watts, Anastasia Khvorova, Andrew H. Coles
Publikováno v:
Molecular Cancer Therapeutics. 17:1251-1258
Glioblastoma (GBM) is the most common and lethal form of primary brain tumor with dismal median and 2-year survivals of 14.5 months and 18%, respectively. The paucity of new therapeutic agents stems from the complex biology of a highly adaptable tumo
Autor:
Bruno M.D.C. Godinho, Melissa J. Moore, Anton A. Turanov, Anastasia Khvorova, David V. Morrissey, Neil Aronin, S. Ananth Karumanchi, Matthew R. Hassler, Dimas Echeverria, Julia F. Alterman, Loic Roux, William Salomon, Reka A. Haraszti, Mehran Nikan, Maire F. Osborn, Sarah M. Davis, Phillip D. Zamore, Andrew H. Coles
Publikováno v:
Nucleic Acids Research
Small interfering RNA (siRNA)-based drugs require chemical modifications or formulation to promote stability, minimize innate immunity, and enable delivery to target tissues. Partially modified siRNAs (up to 70% of the nucleotides) provide significan
Autor:
Andrew H. Coles, Neil Aronin, Lori A. Kennington, Anastasia Khvorova, Maire F. Osborn, Kathryn Chase, Bruno M.D.C. Godinho, Anton A. Turanov, Julia F. Alterman
Publikováno v:
Nucleic Acid Therapeutics. 26:86-92
Preclinical development of RNA interference (RNAi)-based therapeutics requires a rapid, accurate, and robust method of simultaneously quantifying mRNA knockdown in hundreds of samples. The most well-established method to achieve this is quantitative
Autor:
Jonathan K. Watts, Timofei S. Zatsepin, Maire F. Osborn, Anastasia Khvorova, Yury V Martynenko-Makaev, Dimas Echeverria, Socheata Ly, Vivek Sharma, Matthew R. Hassler, Vadim V. Shmanai, Egor A. Ulashchik
Publikováno v:
Bioconjugate chemistry. 29(7)
GalNAc conjugation is emerging as a dominant strategy for delivery of therapeutic oligonucleotides to hepatocytes. The structure and valency of the GalNAc ligand contributes to the potency of the conjugates. Here we present a panel of multivalent Gal
Autor:
Anastasia Khvorova, Maire F. Osborn
Publikováno v:
Nucleic acid therapeutics. 28(3)
RNA interference (RNAi)-based therapeutics are approaching clinical approval for genetically defined diseases. Current clinical success is a result of significant innovations in the development of chemical architectures that support sustained, multi-